Boston Scientific Corporation (BSX) reported its financial results for the first quarter ended March 31, 2026, on Wednesday, April 22. The company announced net sales of $5.203 billion, representing an 11.6 percent increase on a reported basis and an 11.9 percent increase on an organic basis compared to the same period in 2025. Adjusted earnings per share (EPS) for the quarter reached $0.80, exceeding the company's previous guidance range and analyst consensus estimates.
The quarterly growth was driven by strong performance across the company’s primary business segments. The Cardiovascular division recorded sales of $3.25 billion, a 13.2 percent increase year-over-year. Within this segment, Electrophysiology and Structural Heart products showed significant momentum, particularly in international markets. The MedSurg segment reported sales of $1.95 billion, up 9.1 percent from the prior year, supported by gains in the Endoscopy and Urology businesses.
Geographically, sales in the United States grew by 12.4 percent, while international markets saw a 10.5 percent increase. Performance in emerging markets was a highlight, with a 15.1 percent growth rate on a reported basis. The company’s operating margin for the quarter was 26.4 percent on an adjusted basis, which management attributed to continued focus on operational efficiencies and volume growth, despite ongoing inflationary pressures in the global supply chain.
Despite the robust first-quarter results, Boston Scientific adjusted its financial outlook for the remainder of 2026. The company now expects full-year adjusted EPS to fall between $3.34 and $3.41, a reduction from its previous forecast. Management cited anticipated challenges for the adjustment, including increased research and development costs associated with the acceleration of several key clinical trials and potential foreign exchange headwinds impacting international revenue conversion.
Chairman and Chief Executive Officer Michael F. Mahoney stated that the company’s diversified portfolio and global scale allowed it to navigate a complex operating environment effectively during the first quarter. Mahoney noted that while the company remains confident in its long-term growth strategy and product pipeline, the revised guidance reflects a prudent approach to evolving macroeconomic conditions and specific investment requirements planned for the second half of the year.
On a GAAP basis, net income for the first quarter was $645 million, or $0.44 per share, compared to $590 million, or $0.40 per share, in the first quarter of 2025. The difference between GAAP and adjusted figures primarily relates to amortization expense, acquisition-related charges, and restructuring costs. The company ended the quarter with approximately $1.2 billion in cash and cash equivalents.